About Occlutech
Occlutech is a company based in Schaffhausen (Switzerland) founded in 2003 by Tor Peters. Occlutech has raised $70.81 million across 2 funding rounds from investors including Carnegie, Fjarde AP-fonden and unknown. Occlutech has completed 1 acquisition, including NonWoTecc Medical. Occlutech offers products and services including Occluders, ATRIAL FLOW REGULATOR, and Accessories. Occlutech operates in a competitive market with competitors including Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
- Headquarter Schaffhausen, Switzerland
- Founders Tor Peters
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Occlutech Holding Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$70.81 M (USD)
in 2 rounds
-
Latest Funding Round
$49.19 M (USD), Series C
Dec 21, 2021
-
Investors
Carnegie
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Occlutech
Occlutech offers a comprehensive portfolio of products and services, including Occluders, ATRIAL FLOW REGULATOR, and Accessories.
Devices for closing heart defects in congenital diseases
Regulator to manage atrial flow and improve heart function
Support tools for cardiac implant procedures and placements
Funding Insights of Occlutech
Occlutech has successfully raised a total of $70.81M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $49.19 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Occlutech
Occlutech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Carnegie, Fjarde AP-fonden and unknown.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Financial services are provided by Carnegie in investment and private banking.
|
Locked | Locked | Locked | |
|
Manages Swedish national pension assets with sustainable investment strategies.
|
Locked | Locked | Locked |
Investor details for Occlutech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Occlutech
Occlutech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NonWoTecc Medical.
Investment portfolio details for Occlutech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vascular prostheses are developed for peripheral and coronary applications.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Occlutech
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Occlutech
Detailed financials for Occlutech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Occlutech Comparisons
Peer comparison for Occlutech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Occlutech
Occlutech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of bioabsorbable synthetic heart valves and vascular grafts
|
|
| Locked | Locked | Locked |
Pediatric cardiac surgical devices are developed for congenital heart defects.
|
|
| Locked | Locked | Locked |
Bioelectronic devices are developed for regenerative medicine therapies.
|
|
| Locked | Locked | Locked |
Structural heart disease conditions are addressed with implant devices.
|
|
| Locked | Locked | Locked |
Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect.
|
Detailed competitors of Occlutech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Occlutech
Complete news archive for Occlutech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Occlutech
Occlutech was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Occlutech is headquartered in Schaffhausen, Switzerland. It is registered at Schaffhausen, Schaffhausen, Switzerland.
Tor Peters is the current CEO of Occlutech. They have also founded this company.
Occlutech is a funded company, having raised a total of $70.81M across 2 funding rounds to date.
Occlutech was founded in 2003 in Schaffhausen, Switzerland, within the cardiovascular medical devices sector. Devices for minimally invasive treatments of congenital heart defects, stroke prevention, and heart failure are developed and supplied. These include ASD occluders, cardiac implants, and accessories targeted at conditions such as Atrial Septal Defect, Patent Foramen Ovale, Left Atrial Appendage closure, Patent Ductus Arteriosus, and paravalvular leaks. Operations focus on structural heart interventions across global markets.
Occlutech's top competitors include Xeltis, PECA Labs and Endonovo Therapeutics.
Occlutech offers Occluders, ATRIAL FLOW REGULATOR, and Accessories.
Occlutech has made 1 acquisition, including NonWoTecc Medical.
Occlutech has 3 investors. Key investors include Carnegie, Fjarde AP-fonden, and unknown.